Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.

@article{Chevallier1995DocetaxelIA,
  title={Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.},
  author={Bernard Chevallier and Pierre Fumoleau and Pierre Kerbrat and V{\'e}ronique Di{\'e}ras and Henri Roch{\'e} and Ivan Krakowski and Nacer Azli and Martine Bayssas and Marie Ange Lentz and M van Glabbeke},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1995},
  volume={13 2},
  pages={314-22}
}
PURPOSE This trial investigated the toxicity and efficacy of docetaxel as first-line chemotherapy in women with heavily pretreated advanced breast cancer. PATIENTS AND METHODS From April 1992 to August 1992, 35 patients with advanced breast cancer from 29 to 65 years of age with a performance status of 0 to 2 were entered onto the study. Docetaxel 100 mg/m2 was administered every 3 weeks as a 1-hour infusion on day 1 without routine premedication for hypersensitivity reactions. Thirty-one… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 73 extracted citations

Phase II study of weekly docetaxel in patients with metastatic breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology • 2002
View 4 Excerpts
Highly Influenced

Metastatic Breast Cancer.

Orthopedic nursing • 2018
View 2 Excerpts

The differences of clinicopathological factors for breast cancer in respect to time of recurrence and effect on recurrence-free survival.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico • 2015
View 1 Excerpt

Similar Papers

Loading similar papers…